ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, further results and analyses were presented from the…
Analyst Comment
CNS market resurgence: a decade-long slump ends with $80bn milestone
Reshoring efforts in US FMCG business begins, but cost increases are likely
Large pharma drug licensing from China hits high at 28% in 2024
NHS England abolished: a bold cure or a risky operation?
ACC 2025: Imbria’s ninerafaxstat data shows potential for cardiometabolic HFpEF
Ukraine ramps up cost-containment measures to “stabilise” retail drug market
Biopharma IPOs showed signs of recovery in 2024
